Literature DB >> 24316239

Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey.

Julia M L Brotherton1, Bette Liu2, Basil Donovan3, John M Kaldor4, Marion Saville5.   

Abstract

BACKGROUND: Accurate estimates of coverage are essential for estimating the population effectiveness of human papillomavirus (HPV) vaccination. Australia has a purpose built National HPV Vaccination Program Register for monitoring coverage, however notification of doses administered to young women in the community during the national catch-up program (2007-2009) was not compulsory. In 2011, we undertook a population-based mobile phone survey of young women to independently estimate HPV vaccination coverage.
METHODS: Randomly generated mobile phone numbers were dialed to recruit women aged 22-30 (age eligible for HPV vaccination) to complete a computer assisted telephone interview. Consent was sought to validate self reported HPV vaccination status against the national register. Coverage rates were calculated based on self report and weighted to the age and state of residence structure of the Australian female population. These were compared with coverage estimates from the register using Australian Bureau of Statistics estimated resident populations as the denominator.
RESULTS: Among the 1379 participants, the national estimate for self reported HPV vaccination coverage for doses 1/2/3, respectively, weighted for age and state of residence, was 64/59/53%. This compares with coverage of 55/45/32% and 49/40/28% based on register records, using 2007 and 2011 population data as the denominators respectively. Some significant differences in coverage between the states were identified. 20% (223) of women returned a consent form allowing validation of doses against the register and provider records: among these women 85.6% (538) of self reported doses were confirmed.
CONCLUSIONS: We confirmed that coverage rates for young women vaccinated in the community (at age 18-26 years) are underestimated by the national register and that under-notification is greater for second and third doses. Using 2011 population estimates, rather than estimates contemporaneous with the program rollout, reduces register-based coverage estimates further because of large population increases due to immigration since the program.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Australia; Human papillomavirus (HPV); Vaccination coverage

Mesh:

Substances:

Year:  2013        PMID: 24316239     DOI: 10.1016/j.vaccine.2013.11.075

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Results of a Multilevel Intervention Trial to Increase Human Papillomavirus (HPV) Vaccine Uptake among Adolescent Girls.

Authors:  Electra D Paskett; Jessica L Krok-Schoen; Michael L Pennell; Cathy M Tatum; Paul L Reiter; Juan Peng; Brittany M Bernardo; Rory C Weier; Morgan S Richardson; Mira L Katz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04       Impact factor: 4.254

2.  Trends in Genital Warts in the Era of Human Papillomavirus Vaccination.

Authors:  William A Calo; Noel T Brewer
Journal:  Sex Transm Dis       Date:  2015-12       Impact factor: 2.830

3.  Associations Between Exposure to and Expression of Negative Opinions About Human Papillomavirus Vaccines on Social Media: An Observational Study.

Authors:  Adam G Dunn; Julie Leask; Xujuan Zhou; Kenneth D Mandl; Enrico Coiera
Journal:  J Med Internet Res       Date:  2015-06-10       Impact factor: 5.428

Review 4.  Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience.

Authors:  Suzanne M Garland; Susanne K Kjaer; Nubia Muñoz; Stan L Block; Darron R Brown; Mark J DiNubile; Brianna R Lindsay; Barbara J Kuter; Gonzalo Perez; Geraldine Dominiak-Felden; Alfred J Saah; Rosybel Drury; Rituparna Das; Christine Velicer
Journal:  Clin Infect Dis       Date:  2016-05-26       Impact factor: 9.079

5.  Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.

Authors:  Kate T Simms; Michaela Hall; Megan A Smith; Jie-Bin Lew; Suzanne Hughes; Susan Yuill; Ian Hammond; Marion Saville; Karen Canfell
Journal:  PLoS One       Date:  2017-01-17       Impact factor: 3.240

6.  Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.

Authors:  Michaela T Hall; Kate T Simms; Jie-Bin Lew; Megan A Smith; Marion Saville; Karen Canfell
Journal:  PLoS One       Date:  2018-02-14       Impact factor: 3.240

Review 7.  Human papillomavirus vaccination: the population impact.

Authors:  Lai-Yang Lee; Suzanne M Garland
Journal:  F1000Res       Date:  2017-06-12

8.  Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use.

Authors:  Megan A Smith; Dorota Gertig; Michaela Hall; Kate Simms; Jie-Bin Lew; Michael Malloy; Marion Saville; Karen Canfell
Journal:  BMC Health Serv Res       Date:  2016-04-26       Impact factor: 2.655

9.  Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data.

Authors:  Megan A Smith; Bette Liu; Peter McIntyre; Robert Menzies; Aditi Dey; Karen Canfell
Journal:  BMC Infect Dis       Date:  2016-02-01       Impact factor: 3.090

10.  Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.

Authors:  Karen Canfell; Marion Saville; Michael Caruana; Val Gebski; Jessica Darlington-Brown; Julia Brotherton; Stella Heley; Philip E Castle
Journal:  BMJ Open       Date:  2018-01-26       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.